24
Participants
Start Date
October 18, 2021
Primary Completion Date
October 21, 2022
Study Completion Date
October 21, 2022
611 150mg
subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
611 300mg
subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
611 600mg
subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Placebo
During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
Peking University Shougang Hospital, Beijing
The First of Hospital China Medical University, Shenyang
The First Affiliated Hospital of Wannan Medical College, Wuhu
Dermatology Hospital of Jiangxi Province, Nanchang
Nanyang First People's Hospital, Nanyang
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
INDUSTRY